Hwang Sutaeg A, Wilcox George L
Department of Pharmacology, and VA Psychiatry Service, University of Minnesota Medical School, Minneapolis, MN 55455 U.S.A.
Pain. 1987 Mar;28(3):343-355. doi: 10.1016/0304-3959(87)90068-6.
Antinociceptive activities of heterocyclic antidepressants (HCAs) were studied after intrathecal (i.t.) administration in mice. HCAs with selective norepinephrine reuptake blocking properties (noradrenergic HCAs), such as desipramine and protriptyline, produced different antinociceptive profiles from HCAs with selective serotonin reuptake blocking properties (serotonergic HCAs), such as fluoxetine and citalopram. Noradrenergic HCAs were antinociceptive in all of the three nociceptive tests employed in the present study, i.e., tail-flick (TF) test, i.t. substance P-induced behavioral (SPB) test and intradermal hypertonic saline-induced behavioral (HSB) test. Intrathecal noradrenergic HCAs potentiated systemic or i.t. morphine-induced antinociception in the TF test. Serotonergic HCAs were partially antinociceptive in the SPB and HSB test, but inactive in the TF test. Furthermore, serotonergic HCAs did not enhance the antinociception produced by systemic or intrathecal morphine. The present data suggest that the efficacy of HCAs in the control of chronic pain stems, at least partially, from their action in the spinal cord, their analgesic activities probably involve blockade of monoamine reuptake. and the spinal serotonergic system probably possesses a dual action in regard to spinal nociception, while the noradrenergic system does not.
在小鼠鞘内注射后,研究了杂环抗抑郁药(HCA)的抗伤害感受活性。具有选择性去甲肾上腺素再摄取阻断特性的HCA(去甲肾上腺素能HCA),如地昔帕明和普罗替林,与具有选择性5-羟色胺再摄取阻断特性的HCA(5-羟色胺能HCA),如氟西汀和西酞普兰,产生了不同的抗伤害感受谱。去甲肾上腺素能HCA在本研究采用的所有三种伤害感受测试中均具有抗伤害感受作用,即甩尾(TF)试验、鞘内注射P物质诱导的行为(SPB)试验和皮内注射高渗盐水诱导的行为(HSB)试验。鞘内注射去甲肾上腺素能HCA在TF试验中增强了全身或鞘内注射吗啡诱导的抗伤害感受作用。5-羟色胺能HCA在SPB和HSB试验中具有部分抗伤害感受作用,但在TF试验中无活性。此外,5-羟色胺能HCA并未增强全身或鞘内注射吗啡产生的抗伤害感受作用。目前的数据表明,HCA在控制慢性疼痛方面的疗效至少部分源于它们在脊髓中的作用,它们的镇痛活性可能涉及单胺再摄取的阻断。并且脊髓5-羟色胺能系统在脊髓伤害感受方面可能具有双重作用,而去甲肾上腺素能系统则不然。